The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Elderly
NCT ID: NCT05845736
Last Updated: 2023-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
353 participants
OBSERVATIONAL
2022-01-01
2022-12-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Screening of Psycho-cognitive Troubles in Elderly Patients
NCT00831805
Cerebral Haemodynamic Changes During Cognitive Testing: A fTCD Study
NCT03134963
Assessing the Impact of Calcium Channel Blockers on COGnitive Function in the Very Elderly (AI-COG)
NCT01868165
Investigating Neurocognitive Disorders Epidemiology
NCT06375213
Identification of Neurocognitive Disorders by General Practitioners in Primary Care
NCT03678376
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group
absence of neurocognitive disorder (ND), Mini-Mental State Examination (MMSE) from 27 to 30 inclusive
Antihypertensive Agents
number of hypertensive drugs
mild neurocognitive disorder
MMSE from 21 to 26 inclusive
Antihypertensive Agents
number of hypertensive drugs
moderate neurocognitive disorder
MMSE from 11 to 20 inclusive
Antihypertensive Agents
number of hypertensive drugs
severe neurocognitive disorder
MMSE less than or equal to 10
Antihypertensive Agents
number of hypertensive drugs
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antihypertensive Agents
number of hypertensive drugs
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* with history of hypertension and/or on hypertensive drug(s)
Exclusion Criteria
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pr Athanase BENETOS
principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Régional Universitaire de Nancy
Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023PI017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.